| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00216-017-0526-0 |
| P698 | PubMed publication ID | 28762065 |
| P50 | author | Hans H. Maurer | Q52760572 |
| P2093 | author name string | Markus R Meyer | |
| Achim T Caspar | |||
| Folker Westphal | |||
| P2860 | cites work | 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug | Q26822943 |
| Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature | Q26865329 | ||
| Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists | Q28265476 | ||
| High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum | Q33829385 | ||
| Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept | Q33887048 | ||
| Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse | Q34129558 | ||
| 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. | Q34300481 | ||
| 2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. | Q34325128 | ||
| Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series | Q34348317 | ||
| Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response | Q34369264 | ||
| Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. | Q34396223 | ||
| The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample | Q34406732 | ||
| "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion | Q34453002 | ||
| N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues | Q34455931 | ||
| Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps | Q34489642 | ||
| Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS. | Q34490537 | ||
| In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS. | Q35779974 | ||
| Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs | Q35781608 | ||
| Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper | Q36062676 | ||
| High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens | Q37630040 | ||
| 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. | Q37633498 | ||
| Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death | Q37672302 | ||
| Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication | Q37728569 | ||
| Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014. | Q38588257 | ||
| Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples | Q38732154 | ||
| What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? | Q38763388 | ||
| 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry | Q39569585 | ||
| Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs | Q40275494 | ||
| Mechanism of ethylbenzene-induced mouse-specific lung tumor: metabolism of ethylbenzene by rat, mouse, and human liver and lung microsomes | Q46202063 | ||
| Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and | Q46450715 | ||
| Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry. | Q47921568 | ||
| Metabolic Fate of Hallucinogenic NBOMes | Q49148401 | ||
| Metabolism of ethylbenzene in the rat during long-term intermittent inhalation exposure | Q49178243 | ||
| Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine. | Q50673261 | ||
| Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. | Q51166112 | ||
| Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. | Q53063534 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 16 | |
| P304 | page(s) | 897-912 | |
| P577 | publication date | 2017-07-31 | |
| P1433 | published in | Analytical and Bioanalytical Chemistry | Q2845280 |
| P1476 | title | LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening pow | |
| P478 | volume | 410 |
| Q89568147 | In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases |
| Q96950659 | Inter-laboratory reproducibility of an untargeted metabolomics GC-MS assay for analysis of human plasma |
| Q92041409 | Multimodal imaging of hallucinogens 25C- and 25I-NBOMe on blotter papers |
| Q90344547 | NBOMes-Highly Potent and Toxic Alternatives of LSD |
| Q91833440 | Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings |
| Q90262579 | Studies on the in vitro and in vivo metabolism of the synthetic opioids U-51754, U-47931E, and methoxyacetylfentanyl using hyphenated high-resolution mass spectrometry |
| Q64103143 | Untargeted metabolomics by high resolution mass spectrometry coupled to normal and reversed phase liquid chromatography as a tool to study the in vitro biotransformation of new psychoactive substances |
Search more.